Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study
Clinical & Translational Immunology ( IF 5.8 ) Pub Date : 2020-10-14 , DOI: 10.1002/cti2.1192
Ziyun Shao ₁ , Yongwen Feng _{2,

3} , Li Zhong ₄ , Qifeng Xie ₅ , Ming Lei ₆ , Zheying Liu ₅ , Conglin Wang ₅ , Jingjing Ji ₅ , Huiheng Liu ₇ , Zhengtao Gu ₈ , Zhongwei Hu ₆ , Lei Su ₅ , Ming Wu _{2,

5} , Zhifeng Liu _{5,

9}

Affiliation

Department of Nephrology General Hospital of Central Theater Command of PLA Wuhan 430070 China.
Department of Critical Care Medicine and Hospital Infection Prevention and Control The Second People's Hospital of Shenzhen & First Affiliated Hospital of Shenzhen University Health Science Center Shenzhen 518035 China.
Department of Critical Care Medicine The Third People's Hospital of Shenzhen Shenzhen 518035 China.
Department of Critical Care Medicine The First Affiliated Hospital Guizhou University of Chinese Medicine Guiyang 550001 China.
Department of Critical Care Medicine General Hospital of Southern Theater Command of PLA Guangzhou 510010 China.
Department of Nephrology Guangzhou Eighth people's hospital Guangzhou Medical University Guangzhou 510060 China.
Department of Emergency Zhongshan Hospital of Xiamen University Xiamen 361000 China.
Department of Treatment Center for Traumatic Injuries The Third Affiliated Hospital Academy of Orthopedics Guangdong Province Southern Medical University Guangzhou Guangdong 515630 China.
Key Laboratory of Hot Zone Trauma Care and Tissue Repair of PLA General Hospital of Southern Theater Command of PLA Guangzhou 510010 China.

Coronavirus disease 2019 (COVID‐19) outbreak is a major challenge all over the world, without acknowledged treatment. Intravenous immunoglobulin (IVIG) has been recommended to treat critical coronavirus disease 2019 (COVID‐19) patients in a few reviews, but the clinical study evidence on its efficacy in COVID‐19 patients was lacking.

中文翻译：

静脉注射免疫球蛋白治疗 COVID-19 危重患者的临床疗效：一项多中心回顾性队列研究

没有公认的治疗方法，2019 年冠状病毒病 (COVID‐19) 的爆发是全世界的一项重大挑战。静脉注射免疫球蛋白 (IVIG) 已被推荐用于治疗 2019 年重症冠状病毒病 (COVID-19) 患者，但缺乏关于其在 COVID-19 患者中疗效的临床研究证据。

更新日期：2020-10-16

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>